GSK (LON:GSK) Stock Keeps Buy Rating at Berenberg Bank

GSK (LON:GSK)‘s stock had its “buy” rating reiterated by Berenberg Bank in a research report issued to clients and investors on Tuesday, Digital Look reports. They presently have a GBX 2,200 price target on the stock. Berenberg Bank‘s price objective indicates a potential upside of 20.12% from the stock’s previous close.

Several other equities analysts also recently issued reports on GSK. Deutsche Bank Aktiengesellschaft restated a “hold” rating and issued a GBX 2,000 price objective on shares of GSK in a research note on Thursday, October 29th. Royal Bank Of Canada assumed coverage on GSK in a research report on Tuesday, September 8th. They set a “sector perform” rating and a GBX 1,975 target price on the stock. Finally, Jefferies Financial Group reissued a “buy” rating and issued a GBX 2,500 target price on shares of GSK in a report on Tuesday, October 20th. Three research analysts have rated the stock with a Buy rating, four have given a Hold rating and one has given a Sell rating to the stock. According to MarketBeat, the company presently has a consensus rating of “Hold” and a consensus price target of GBX 2,064.38.

GSK Price Performance

Shares of LON GSK opened at GBX 1,831.50 on Tuesday. The stock’s 50-day moving average is GBX 1,843.60 and its two-hundred day moving average is GBX 1,948.72. The company has a debt-to-equity ratio of 126.38, a current ratio of 0.86 and a quick ratio of 0.73. GSK has a 1-year low of GBX 1,690 and a 1-year high of GBX 2,282. The company has a market cap of £73.39 billion, a price-to-earnings ratio of 15.55, a price-to-earnings-growth ratio of 1.24 and a beta of 0.28.

GSK (LON:GSK) last posted its quarterly earnings results on Wednesday, October 28th. The company reported GBX 54.60 EPS for the quarter. The company had revenue of GBX 888.70 billion during the quarter. GSK had a net margin of 12.97% and a return on equity of 24.64%. Analysts forecast that GSK will post 175.98 EPS for the current fiscal year.

Insider Buying and Selling at GSK

In other GSK news, insider Jonathan Symonds acquired 1,500 shares of the company’s stock in a transaction on Friday, September 18th. The shares were bought at an average cost of GBX 1,881 per share, for a total transaction of £28,215. Also, insider Anne Beal bought 637 shares of GSK stock in a transaction dated Friday, September 18th. The stock was acquired at an average cost of GBX 4,985 per share, with a total value of £31,754.45. Insiders have acquired a total of 2,151 shares of company stock worth $6,021,921 over the last three months. 0.20% of the stock is currently owned by insiders.

GSK Company Profile

GSK plc, together with its subsidiaries, engages in the research, development, and manufacture of vaccines, and specialty and general medicines to prevent and treat disease in the United Kingdom, the United States, and internationally. It operates through two segments, Commercial Operations and Total R&D. The company offers shingles, meningitis, respiratory syncytial virus, flu, polio, influenza, and pandemic vaccines. It also provides medicines for HIV, oncology, respiratory/immunology, and other specialty medicine products, as well as inhaled medicines for asthma and chronic obstructive pulmonary disease, and antibiotics for infections.